{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:48:14Z","timestamp":1790261294074,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T00:00:00Z","timestamp":1498608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40265-017-0781-6","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T04:43:34Z","timestamp":1498625014000},"page":"1377-1387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-1838","authenticated-orcid":false,"given":"Bernard","family":"Bannwarth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Kostine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,28]]},"reference":[{"key":"781_CR1","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(11)60402-9","volume":"377","author":"DC Turk","year":"2011","unstructured":"Turk DC, Wilson HD, Canaha A. Treatment of chronic non-cancer pain. Lancet. 2011;377:2226\u201335.","journal-title":"Lancet."},{"key":"781_CR2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.7326\/M16-2458","volume":"166","author":"R Chou","year":"2017","unstructured":"Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166:480\u201392.","journal-title":"Ann Intern Med."},{"key":"781_CR3","doi-asserted-by":"crossref","first-page":"f7339","DOI":"10.1136\/bmj.f7339","volume":"347","author":"E Kalso","year":"2013","unstructured":"Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ. 2013;347:f7339.","journal-title":"BMJ."},{"key":"781_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acs.jmedchem.6b00964","volume":"60","author":"BH Norman","year":"2017","unstructured":"Norman BH, McDermott JS. Targeting the nerve growth factor (NGF) pathway in drug discovery: potential applications to new therapies for chronic pain. J Med Chem. 2017;60:66\u201388.","journal-title":"J Med Chem."},{"key":"781_CR5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40265-014-0208-6","volume":"74","author":"B Bannwarth","year":"2014","unstructured":"Bannwarth B, Kostine M. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists? Drugs. 2014;74:619\u201326.","journal-title":"Drugs."},{"key":"781_CR6","unstructured":"Taylor P. J & J drops NGF blocker fulranumab. PMLiVE, 4 April 2016. Available from: \n                        http:\/\/www.pmlive.com\/pharma_news\/j_and_j_drops_ngf_blocker_fulranumab_968433\n                        \n                    . Accessed 13 Apr 2017."},{"issue":"Suppl. 1","key":"781_CR7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.joca.2014.09.002","volume":"23","author":"CG Miller","year":"2015","unstructured":"Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthr Cartil. 2015;23(Suppl. 1):S3\u20137.","journal-title":"Osteoarthr Cartil."},{"issue":"Suppl. 1","key":"781_CR8","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.joca.2014.10.003","volume":"23","author":"TJ Schnitzer","year":"2015","unstructured":"Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthr Cartil. 2015;23(Suppl. 1):S8\u201317.","journal-title":"Osteoarthr Cartil."},{"key":"781_CR9","first-page":"E45","volume":"17","author":"VF Leite","year":"2014","unstructured":"Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and meta-analysis. Pain Phys. 2014;17:E45\u201360.","journal-title":"Pain Phys."},{"key":"781_CR10","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1016\/j.pain.2011.05.003","volume":"152","author":"N Katz","year":"2011","unstructured":"Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain. 2011;152:2248\u201358.","journal-title":"Pain."},{"key":"781_CR11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pain.2013.03.006","volume":"154","author":"AJ Kivitz","year":"2013","unstructured":"Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain. 2013;154:1009\u201321.","journal-title":"Pain."},{"key":"781_CR12","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.091444","volume":"38","author":"C Bombardier","year":"2011","unstructured":"Bombardier C, Evans CJ, Katz N, et al. Further qualification of therapeutic responder index for patients with chronic low back pain. J Rheumatol. 2011;38:362\u20139.","journal-title":"J Rheumatol."},{"key":"781_CR13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.clinthera.2016.03.030","volume":"38","author":"P Sanga","year":"2016","unstructured":"Sanga P, Polverejan E, Wang S, et al. Efficacy, safety, and tolerability of fulranumab as an adjunctive therapy in patients with inadequately controlled, moderate-to-severe chronic low back pain: a randomized, double-blind, placebo-controlled, dose-ranging, dose-loading phase II study. Clin Ther. 2016;38:1435\u201350.","journal-title":"Clin Ther."},{"key":"781_CR14","first-page":"523","volume":"7","author":"PJ Tiseo","year":"2014","unstructured":"Tiseo PJ, Ren H, Mellis S. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. J Pain Res. 2014;7:523\u201330.","journal-title":"J Pain Res."},{"key":"781_CR15","unstructured":"Regeneron Pharmaceuticals. Regeneron and Teva provide update on fasinumab clinical development programs. Available from: \n                        http:\/\/www.prnewswire.com\/news-releases\/regeneron-and-teva-provide-update-on-fasinumab-clinical-development-programs-300345603.html\n                        \n                    . Accessed 13 Apr 2017."},{"key":"781_CR16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/pme.12677","volume":"16","author":"C Bramson","year":"2015","unstructured":"Bramson C, Herrmann DN, Carey W, et al. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015;16:1163\u201376.","journal-title":"Pain Med."},{"key":"781_CR17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.0000000000000686","volume":"83","author":"H Wang","year":"2014","unstructured":"Wang H, Romano G, Frustaci ME, et al. Fulranumab for treatment of diabetic peripheral neuropathic pain: a randomized controlled trial. Neurology. 2014;83:628\u201337.","journal-title":"Neurology"},{"key":"781_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/AJP.0000000000000388","volume":"33","author":"H Wang","year":"2017","unstructured":"Wang H, Romano G, Fedgchin M, et al. Fulranumab in pain associated with postherpetic neuralgia and posttraumatic neuropathy: efficacy, safety, and tolerability results from a randomized, double-blind, placebo-controlled, phase-2 study. Clin J Pain. 2017;33:99\u2013108.","journal-title":"Clin J Pain."},{"key":"781_CR19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1744-8069-8-59","volume":"8","author":"S Unezaki","year":"2012","unstructured":"Unezaki S, Sasaki A, Mabuchi T, et al. Involvement of Tyr1472 phosphorylation of NMDA receptor NR2B subunit in postherpetic neuralgia in model mice. Mol Pain. 2012;8:59.","journal-title":"Mol Pain."},{"key":"781_CR20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/j.pain.0000000000000211","volume":"156","author":"M Sopata","year":"2015","unstructured":"Sopata M, Katz N, Carey W, et al. Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain. 2015;156:1703\u201313.","journal-title":"Pain."},{"issue":"Suppl. 4","key":"781_CR21","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jpain.2016.01.359","volume":"17","author":"N Slatkin","year":"2016","unstructured":"Slatkin N, Zaki N, Sanga P, et al. Efficacy, safety, and tolerability of fulranumab as an adjunctive therapy for cancer-related pain: a randomized, double-blind, placebo-controlled, multicenter study [abstract]. J Pain. 2016;17(Suppl. 4):S70\u20131.","journal-title":"J Pain."},{"key":"781_CR22","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.juro.2015.10.178","volume":"195","author":"JC Nickel","year":"2016","unstructured":"Nickel JC, Mills IW, Crook TJ, et al. Tanezumab reduces pain in women with interstitial cystitis\/bladder pain syndrome and patients with nonurological associated somatic syndrome. J Urol. 2016;195:942\u20138.","journal-title":"J Urol."},{"key":"781_CR23","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1016\/j.juro.2010.12.088","volume":"85","author":"RJ Evans","year":"2011","unstructured":"Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;85:1716\u201321.","journal-title":"J Urol."},{"key":"781_CR24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.urology.2012.07.035","volume":"80","author":"JC Nickel","year":"2012","unstructured":"Nickel JC, Atkinson G, Krieger JN, et al. Preliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis\/chronic pelvic pain syndrome. Urology. 2012;80:1105\u201310.","journal-title":"Urology."},{"issue":"Suppl. 1","key":"781_CR25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000052075","volume":"41","author":"CA Rask","year":"1999","unstructured":"Rask CA. Biological actions of nerve growth factor in the peripheral nervous system. Eur Neurol. 1999;41(Suppl. 1):14\u20139.","journal-title":"Eur Neurol."},{"key":"781_CR26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jns.2014.07.028","volume":"345","author":"MT Brown","year":"2014","unstructured":"Brown MT, Herrmann DN, Goldstein M, et al. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014;345:139\u201347.","journal-title":"J Neurol Sci."},{"key":"781_CR27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.39492","volume":"68","author":"MC Hochberg","year":"2016","unstructured":"Hochberg MC, Tive LA, Abramson SB, et al. When is osteonecrosis not osteonecrosis? Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthr Rheumatol. 2016;68:382\u201391.","journal-title":"Arthr Rheumatol."},{"key":"781_CR28","unstructured":"JNJ-42160443 (fulranumab) Advisory Committee briefing document, Janssen Research & Development, L.L.C., 31 January 2012. Available from: \n                        https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AthritisAdvisoryCommittee\/UCM295204.pdf\n                        \n                    . Accessed 13 Apr 2017."},{"key":"781_CR29","unstructured":"REGN475 briefing book for Arthritis Advisory Committee Meeting. Regeneron, March 2012. Available from: \n                        https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AthritisAdvisoryCommittee\/UCM295206.pdf\n                        \n                    . Accessed 13 Apr 2017."},{"key":"781_CR30","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee Meeting, 2012. Available from: \n                        https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AthritisAdvisoryCommittee\/UCM286552.pdf\n                        \n                    . Accessed 13 Apr 2017."},{"key":"781_CR31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.39493","volume":"68","author":"AJ Teichtahl","year":"2016","unstructured":"Teichtahl AJ, Cicuttini FM. Pain relief: the potential for a perfect storm. Arthr Rheumatol. 2016;68:270\u20133.","journal-title":"Arthr Rheumatol."},{"key":"781_CR32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","volume":"55","author":"T Schaeverbeke","year":"2016","unstructured":"Schaeverbeke T, Truchetet ME, Kostine M, et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55:210\u201320.","journal-title":"Rheumatology (Oxford)."},{"key":"781_CR33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.joca.2011.01.009","volume":"19","author":"TJ Schnitzer","year":"2011","unstructured":"Schnitzer TJ, Lane NE, Birbara C, et al. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil. 2011;19:639\u201346.","journal-title":"Osteoarthr Cartil."},{"key":"781_CR34","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.pain.2014.06.004","volume":"155","author":"JS Gimbel","year":"2014","unstructured":"Gimbel JS, Kivitz AJ, Bramson C, et al. Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain. 2014;155:1793\u2013801.","journal-title":"Pain."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0781-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T06:27:14Z","timestamp":1539757634000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,28]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0781-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,28]]}}}